04:42:42 Europe / Stockholm

Svenska | English

Alvotech

Kalender

2023-11-14	Kvartalsrapport 2023-Q3
2023-08-17	Kvartalsrapport 2023-Q2
2023-06-06	Årsstämma 2023
2023-05-19	Kvartalsrapport 2023-Q1

Beskrivning

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

Filter

År

Typ

Språk

Rensa

2023-11-29 10:00:00 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® -3,12% | 399 MISK

2023-11-29 10:00:00 Alvotech kynnir jákvæðar niðurstöður úr rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria® -3,12% | 399 MISK

2023-11-29 10:00:00 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® -3,12% | 399 MISK

2023-11-28 22:15:00 Alvotech birtir uppgjör fyrir fyrstu níu mánuði ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðungi -1,81% | 105 MISK

2023-11-28 22:15:00 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update -1,81% | 105 MISK

2023-11-28 22:15:00 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update -1,81% | 105 MISK

2023-11-21 14:00:00 Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET +1,19% | 16,1 MISK

2023-11-21 14:00:00 Alvotech mun birta uppgjör fyrstu níu mánaða 2023 þann 28. nóvember og streyma uppgjörsfundi 29. nóvember kl. 13:00 að íslenskum tíma +1,19% | 16,1 MISK

2023-11-14 13:00:00 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab) +1,54% | 247 MISK

2023-11-14 13:00:00 Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara +1,54% | 247 MISK

2023-11-14 13:00:00 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab) +1,54% | 247 MISK

2023-11-10 15:30:00 STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara +6,50% | 259 MISK

2023-11-10 15:30:00 Alvotech og STADA fyrst til að hljóta jákvæða afgreiðslu lyfjastofnunar Evrópu á umsókn um markaðsleyfi fyrir líftæknilyfjahliðstæðu við Stelara +6,50% | 259 MISK

2023-11-10 15:30:00 STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara +6,50% | 259 MISK

2023-11-07 14:00:00 Alvotech tekur þátt í heilbrigðisráðstefnu Jefferies í London -0,82% | 18,7 MISK

2023-11-07 14:00:00 Alvotech to Present at the Jefferies 2023 London Healthcare Conference -0,82% | 18,7 MISK

2023-10-12 10:00:00 Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 -2,35% | 135 MISK

2023-10-12 10:00:00 Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT04 í Bandaríkjunum -2,35% | 135 MISK

2023-10-12 10:00:00 Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 -2,35% | 135 MISK

2023-10-05 19:21:02 Alvotech og Íslandsbanki gera samning um viðskiptavakt með hlutabréf í Kauphöllinni -0,78% | 26,1 MISK

2023-10-05 19:21:02 Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland -0,78% | 26,1 MISK

2023-10-03 11:00:00 Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) -0,97% | 94,0 MISK

2023-10-03 11:00:00 Alvotech og Kashiv Biosciences ganga til samstarfs um þróun og markaðssetningu fyrirhugaðrar líftæknilyfjahliðstæðu við Xolair (omalizumab) -0,97% | 94,0 MISK

2023-09-25 10:00:00 Markaðsleyfi veitt í Japan fyrir AVT04 (ustekinumab), líftæknilyfjahliðstæðu Alvotech við Stelara® +1,21% | 96,1 MISK

2023-09-25 10:00:00 Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® +1,21% | 96,1 MISK

2023-09-20 10:30:00 Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) +1,23% | 262 MISK

2023-09-20 10:30:00 Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT02 (adalimumab) í Bandaríkjunum +1,23% | 262 MISK

2023-09-20 10:30:00 Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) +1,23% | 262 MISK

2023-09-11 11:00:00 Alvotech tekur þátt í 21. heilbrigðisráðstefnu Morgans Stanleys +0,39% | 39,4 MISK

2023-09-11 11:00:00 Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference +0,39% | 39,4 MISK

2023-09-05 15:30:00 Alvotech Announces Changes to the Leadership Team 0,00% | 51,0 MISK

2023-09-05 15:30:00 Alvotech tilkynnir um breytingar í framkvæmdastjórn 0,00% | 51,0 MISK

2023-09-05 15:30:00 Alvotech Announces Changes to the Leadership Team 0,00% | 51,0 MISK

2023-08-30 22:15:00 Alvotech birtir uppgjör fyrir fyrri helming ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðung +0,78% | 24,3 MISK

2023-08-30 22:15:00 Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update +0,78% | 24,3 MISK

2023-08-29 11:00:00 Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt -1,15% | 118 MISK

2023-08-29 11:00:00 Alvotech og Bioventure fá markaðsleyfi fyrir AVT02 (adalimumab) í Egyptalandi -1,15% | 118 MISK

2023-08-29 11:00:00 Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt -1,15% | 118 MISK

2023-08-22 15:15:00 Alvotech mun birta uppgjör fyrri árshelmings 2023 þann 30. ágúst nk. og streyma uppgjörsfundi 31. ágúst nk. kl. 12:00 að íslenskum tíma +2,30% | 250 MISK

2023-08-22 15:15:00 Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET +2,30% | 250 MISK

2023-07-31 10:00:00 Alvotech lýkur lokuðu skuldabréfaútboði að andvirði 100 milljónir dollara +1,92% | 111 MISK

2023-07-31 10:00:00 Alvotech Completes $100 Million Convertible Bond Private Placement +1,92% | 111 MISK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden